25 XP   0   0   10

Yuyu Pharma Inc
Buy, Hold or Sell?

Let's analyse Yuyu together

PenkeI guess you are interested in Yuyu Pharma Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Yuyu Pharma Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Yuyu Pharma Inc

I send you an email if I find something interesting about Yuyu Pharma Inc.

Quick analysis of Yuyu (30 sec.)










What can you expect buying and holding a share of Yuyu? (30 sec.)

How much money do you get?

How much money do you get?
₩0.00
When do you have the money?
1 year
How often do you get paid?
73.1%

What is your share worth?

Current worth
₩7,464.57
Expected worth in 1 year
₩7,551.27
How sure are you?
69.2%

+ What do you gain per year?

Total Gains per Share
₩86.70
Return On Investment
0.7%

For what price can you sell your share?

Current Price per Share
₩11,580.00
Expected price per share
₩9,920 - ₩13,070
How sure are you?
50%

1. Valuation of Yuyu (5 min.)




Live pricePrice per Share (EOD)

₩11,580.00

Intrinsic Value Per Share

₩-1,413.89 - ₩-1,424.09

Total Value Per Share

₩6,050.68 - ₩6,040.47

2. Growth of Yuyu (5 min.)




Is Yuyu growing?

Current yearPrevious yearGrowGrow %
How rich?$84.5m$88.1m-$2.7m-3.2%

How much money is Yuyu making?

Current yearPrevious yearGrowGrow %
Making money-$1.4m-$967k-$486.1k-33.5%
Net Profit Margin-6.1%-4.2%--

How much money comes from the company's main activities?

3. Financial Health of Yuyu (5 min.)




What can you expect buying and holding a share of Yuyu? (5 min.)

Welcome investor! Yuyu's management wants to use your money to grow the business. In return you get a share of Yuyu.

What can you expect buying and holding a share of Yuyu?

First you should know what it really means to hold a share of Yuyu. And how you can make/lose money.

Speculation

The Price per Share of Yuyu is ₩11,580. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Yuyu.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Yuyu, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is ₩7,464.57. Based on the TTM, the Book Value Change Per Share is ₩21.68 per quarter. Based on the YOY, the Book Value Change Per Share is ₩-138.28 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is ₩0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Yuyu.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 % of Price per Share% of Price per Share% of Price per Share% of Price per Share% of Price per Share
Usd Eps-0.120.0%-0.090.0%-0.060.0%0.000.0%0.040.0%
Usd Book Value Change Per Share-0.040.0%0.020.0%-0.100.0%-0.260.0%0.200.0%
Usd Dividend Per Share0.000.0%0.000.0%0.060.0%0.060.0%0.070.0%
Usd Total Gains Per Share-0.040.0%0.020.0%-0.030.0%-0.200.0%0.270.0%
Usd Price Per Share7.84-9.31-12.18-13.88-13.60-
Price to Earnings Ratio-16.59-571.04--87.61-87.81-73.95-
Price-to-Total Gains Ratio-177.97--22.01--884.36--113.80--76.31-
Price to Book Ratio1.50-1.78-2.30-2.28-2.05-
Price-to-Total Gains Ratio-177.97--22.01--884.36--113.80--76.31-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share8.106
Number of shares123
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.06
Usd Book Value Change Per Share0.02-0.26
Usd Total Gains Per Share0.02-0.20
Gains per Quarter (123 shares)1.87-24.99
Gains per Year (123 shares)7.47-99.94
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
107-328-128-110
2015455-255-210
30221183-383-310
403018111-510-410
503725138-638-510
604532166-766-610
705239194-893-710
806046221-1021-810
906753249-1148-910
1007560277-1276-1010

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share1.03.00.025.0%2.010.00.016.7%9.011.00.045.0%15.011.00.057.7%15.011.00.057.7%
Book Value Change Per Share2.02.00.050.0%4.08.00.033.3%9.011.00.045.0%15.011.00.057.7%15.011.00.057.7%
Dividend per Share0.00.04.00.0%7.00.05.058.3%13.00.07.065.0%19.00.07.073.1%19.00.07.073.1%
Total Gains per Share2.02.00.050.0%7.05.00.058.3%12.08.00.060.0%18.08.00.069.2%18.08.00.069.2%

Fundamentals of Yuyu

About Yuyu Pharma Inc

Yuyu Pharma, Inc. develops and markets pharmaceutical products. The company offers various prescription drugs, non-prescription drugs, quasi-drugs, health functional foods, and other products in the fields of neurology, endocrinology, otolaryngology, etc. The company was formerly known as YuYu Inc. and changed its name to Yuyu Pharma, Inc. in May 2008. Yuyu Pharma, Inc. was founded in 1941 and is headquartered in Jecheon-si, South Korea.

Fundamental data was last updated by Penke on 2024-03-24 00:29:04.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Yuyu Pharma Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Yuyu earns for each ₩1 of revenue.

  • Above 10% is considered healthy but always compare Yuyu to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Net Profit Margin of -8.0% means that ₩-0.08 for each ₩1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Yuyu Pharma Inc:

  • The MRQ is -8.0%. The company is making a loss. -1
  • The TTM is -6.1%. The company is making a loss. -1
Trends
Current periodCompared to+/- 
MRQ-8.0%TTM-6.1%-2.0%
TTM-6.1%YOY-4.2%-1.9%
TTM-6.1%5Y-0.6%-5.5%
5Y-0.6%10Y1.0%-1.6%
1.1.2. Return on Assets

Shows how efficient Yuyu is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Yuyu to the Drug Manufacturers - Specialty & Generic industry mean.
  • -1.4% Return on Assets means that Yuyu generated ₩-0.01 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Yuyu Pharma Inc:

  • The MRQ is -1.4%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -1.0%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-1.4%TTM-1.0%-0.3%
TTM-1.0%YOY-0.7%-0.3%
TTM-1.0%5Y-0.1%-0.9%
5Y-0.1%10Y0.2%-0.3%
1.1.3. Return on Equity

Shows how efficient Yuyu is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Yuyu to the Drug Manufacturers - Specialty & Generic industry mean.
  • -2.4% Return on Equity means Yuyu generated ₩-0.02 for each ₩1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Yuyu Pharma Inc:

  • The MRQ is -2.4%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -1.8%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-2.4%TTM-1.8%-0.6%
TTM-1.8%YOY-1.1%-0.7%
TTM-1.8%5Y-0.2%-1.6%
5Y-0.2%10Y0.2%-0.4%

1.2. Operating Efficiency of Yuyu Pharma Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Yuyu is operating .

  • Measures how much profit Yuyu makes for each ₩1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Yuyu to the Drug Manufacturers - Specialty & Generic industry mean.
  • An Operating Margin of 0.0% means the company generated ₩0.00  for each ₩1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Yuyu Pharma Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.3%+0.3%
TTM-0.3%YOY-0.4%+0.1%
TTM-0.3%5Y4.5%-4.8%
5Y4.5%10Y5.1%-0.6%
1.2.2. Operating Ratio

Measures how efficient Yuyu is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • An Operation Ratio of 1.72 means that the operating costs are ₩1.72 for each ₩1 in net sales.

Let's take a look of the Operating Ratio trends of Yuyu Pharma Inc:

  • The MRQ is 1.716. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.543. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.716TTM1.543+0.173
TTM1.543YOY1.629-0.086
TTM1.5435Y1.460+0.082
5Y1.46010Y1.458+0.003

1.3. Liquidity of Yuyu Pharma Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Yuyu is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A Current Ratio of 1.99 means the company has ₩1.99 in assets for each ₩1 in short-term debts.

Let's take a look of the Current Ratio trends of Yuyu Pharma Inc:

  • The MRQ is 1.990. The company is able to pay all its short-term debts. +1
  • The TTM is 1.741. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ1.990TTM1.741+0.249
TTM1.741YOY2.402-0.661
TTM1.7415Y2.434-0.693
5Y2.43410Y2.309+0.125
1.3.2. Quick Ratio

Measures if Yuyu is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Yuyu to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Quick Ratio of 0.55 means the company can pay off ₩0.55 for each ₩1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Yuyu Pharma Inc:

  • The MRQ is 0.551. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.451. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.551TTM0.451+0.101
TTM0.451YOY0.603-0.152
TTM0.4515Y0.683-0.232
5Y0.68310Y0.676+0.007

1.4. Solvency of Yuyu Pharma Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Yuyu assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Yuyu to Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Asset Ratio of 0.39 means that Yuyu assets are financed with 38.6% credit (debt) and the remaining percentage (100% - 38.6%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Yuyu Pharma Inc:

  • The MRQ is 0.386. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.381. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.386TTM0.381+0.004
TTM0.381YOY0.347+0.035
TTM0.3815Y0.345+0.037
5Y0.34510Y0.345+0.000
1.4.2. Debt to Equity Ratio

Measures if Yuyu is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Yuyu to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Equity ratio of 67.0% means that company has ₩0.67 debt for each ₩1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Yuyu Pharma Inc:

  • The MRQ is 0.670. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.655. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.670TTM0.655+0.015
TTM0.655YOY0.553+0.102
TTM0.6555Y0.550+0.105
5Y0.55010Y0.549+0.001

2. Market Valuation of Yuyu Pharma Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every ₩1 in earnings Yuyu generates.

  • Above 15 is considered overpriced but always compare Yuyu to the Drug Manufacturers - Specialty & Generic industry mean.
  • A PE ratio of -16.59 means the investor is paying ₩-16.59 for every ₩1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Yuyu Pharma Inc:

  • The EOD is -17.153. Based on the earnings, the company is expensive. -2
  • The MRQ is -16.590. Based on the earnings, the company is expensive. -2
  • The TTM is 571.036. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-17.153MRQ-16.590-0.563
MRQ-16.590TTM571.036-587.626
TTM571.036YOY-87.607+658.643
TTM571.0365Y87.810+483.226
5Y87.81010Y73.946+13.864
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Yuyu Pharma Inc:

  • The EOD is -12.407. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -11.999. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -15.110. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-12.407MRQ-11.999-0.407
MRQ-11.999TTM-15.110+3.111
TTM-15.110YOY-62.241+47.131
TTM-15.1105Y-35.987+20.877
5Y-35.98710Y-21.349-14.637
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Yuyu is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A PB ratio of 1.50 means the investor is paying ₩1.50 for each ₩1 in book value.

Let's take a look of the Price to Book Ratio trends of Yuyu Pharma Inc:

  • The EOD is 1.551. Based on the equity, the company is underpriced. +1
  • The MRQ is 1.500. Based on the equity, the company is underpriced. +1
  • The TTM is 1.778. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD1.551MRQ1.500+0.051
MRQ1.500TTM1.778-0.278
TTM1.778YOY2.298-0.520
TTM1.7785Y2.278-0.500
5Y2.27810Y2.050+0.228
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Yuyu Pharma Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---62.93021.676-390%-138.281+120%-370.523+489%287.099-122%
Book Value Per Share--7464.5697480.4050%7561.465-1%9521.003-22%10562.662-29%
Current Ratio--1.9901.741+14%2.402-17%2.434-18%2.309-14%
Debt To Asset Ratio--0.3860.381+1%0.347+11%0.345+12%0.345+12%
Debt To Equity Ratio--0.6700.655+2%0.553+21%0.550+22%0.549+22%
Dividend Per Share----0%91.578-100%80.331-100%105.050-100%
Eps---168.774-130.659-23%-87.217-48%3.480-4949%54.138-412%
Free Cash Flow Per Share---233.345-265.951+14%-182.118-22%-114.136-51%-129.942-44%
Free Cash Flow To Equity Per Share---233.345-310.737+33%-257.328+10%-125.143-46%-32.837-86%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---1424.094--------
Intrinsic Value_10Y_min---1413.890--------
Intrinsic Value_1Y_max---564.966--------
Intrinsic Value_1Y_min---555.182--------
Intrinsic Value_3Y_max---1375.683--------
Intrinsic Value_3Y_min---1319.838--------
Intrinsic Value_5Y_max---1798.431--------
Intrinsic Value_5Y_min---1696.955--------
Market Cap67855094400.000-167%181245937600.000216996186400.000-16%289810954800.000-37%257751510205.000-30%222779630926.923-19%
Net Profit Margin---0.080-0.061-24%-0.042-48%-0.006-93%0.010-864%
Operating Margin----0.0030%-0.0040%0.045-100%0.051-100%
Operating Ratio--1.7161.543+11%1.629+5%1.460+17%1.458+18%
Pb Ratio1.551+3%1.5001.778-16%2.298-35%2.278-34%2.050-27%
Pe Ratio-17.153-3%-16.590571.036-103%-87.607+428%87.810-119%73.946-122%
Price Per Share11580.000+3%11200.00013300.000-16%17400.000-36%19825.000-44%19432.692-42%
Price To Free Cash Flow Ratio-12.407-3%-11.999-15.110+26%-62.241+419%-35.987+200%-21.349+78%
Price To Total Gains Ratio-184.013-3%-177.975-22.013-88%-884.365+397%-113.799-36%-76.309-57%
Quick Ratio--0.5510.451+22%0.603-9%0.683-19%0.676-18%
Return On Assets---0.014-0.010-24%-0.007-48%-0.001-92%0.002-895%
Return On Equity---0.024-0.018-25%-0.011-53%-0.002-91%0.002-1117%
Total Gains Per Share---62.93021.676-390%-46.703-26%-290.191+361%392.149-116%
Usd Book Value--84557674.70585398287.126-1%88159588.190-4%77358339.356+9%72791304.198+16%
Usd Book Value Change Per Share---0.0440.015-390%-0.097+120%-0.259+489%0.201-122%
Usd Book Value Per Share--5.2255.2360%5.293-1%6.665-22%7.394-29%
Usd Dividend Per Share----0%0.064-100%0.056-100%0.074-100%
Usd Eps---0.118-0.091-23%-0.061-48%0.002-4949%0.038-412%
Usd Free Cash Flow---2643306.323-3037112.950+15%-2123326.653-20%-1397129.350-47%-1247583.656-53%
Usd Free Cash Flow Per Share---0.163-0.186+14%-0.127-22%-0.080-51%-0.091-44%
Usd Free Cash Flow To Equity Per Share---0.163-0.218+33%-0.180+10%-0.088-46%-0.023-86%
Usd Market Cap47498566.080-167%126872156.320151897330.480-16%202867668.360-37%180426057.144-30%155945741.649-19%
Usd Price Per Share8.106+3%7.8409.310-16%12.180-36%13.878-44%13.603-42%
Usd Profit---1911849.240-1453114.668-24%-967007.841-49%-260093.861-86%19549.692-9879%
Usd Revenue--23863610.62424034420.874-1%23675760.399+1%19887218.953+20%18617396.750+28%
Usd Total Gains Per Share---0.0440.015-390%-0.033-26%-0.203+361%0.275-116%
 EOD+3 -5MRQTTM+10 -22YOY+8 -265Y+9 -2610Y+5 -30

3.2. Fundamental Score

Let's check the fundamental score of Yuyu Pharma Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-17.153
Price to Book Ratio (EOD)Between0-11.551
Net Profit Margin (MRQ)Greater than0-0.080
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.551
Current Ratio (MRQ)Greater than11.990
Debt to Asset Ratio (MRQ)Less than10.386
Debt to Equity Ratio (MRQ)Less than10.670
Return on Equity (MRQ)Greater than0.15-0.024
Return on Assets (MRQ)Greater than0.05-0.014
Total3/10 (30.0%)

3.3. Technical Score

Let's check the technical score of Yuyu Pharma Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5033.203
Ma 20Greater thanMa 5012,106.000
Ma 50Greater thanMa 10012,451.800
Ma 100Greater thanMa 20012,924.000
OpenGreater thanClose11,740.000
Total2/5 (40.0%)



Latest Balance Sheet

Balance Sheet of 2023-09-30. Currency in KRW. All numbers in thousands.

Summary
Total Assets196,582,950
Total Liabilities75,786,271
Total Stockholder Equity113,137,529
 As reported
Total Liabilities 75,786,271
Total Stockholder Equity+ 113,137,529
Total Assets = 196,582,950

Assets

Total Assets196,582,950
Total Current Assets94,094,809
Long-term Assets102,488,140
Total Current Assets
Cash And Cash Equivalents 18,010,839
Short-term Investments 1,000,000
Net Receivables 25,067,536
Inventory 43,252,932
Other Current Assets 401,454
Total Current Assets  (as reported)94,094,809
Total Current Assets  (calculated)87,732,761
+/- 6,362,048
Long-term Assets
Property Plant Equipment 81,880,009
Goodwill 155,309
Intangible Assets 3,675,059
Long-term Assets Other 262,301
Long-term Assets  (as reported)102,488,140
Long-term Assets  (calculated)85,972,678
+/- 16,515,462

Liabilities & Shareholders' Equity

Total Current Liabilities47,273,214
Long-term Liabilities28,513,058
Total Stockholder Equity113,137,529
Total Current Liabilities
Short Long Term Debt 21,466,620
Accounts payable 9,179,299
Other Current Liabilities 9,565
Total Current Liabilities  (as reported)47,273,214
Total Current Liabilities  (calculated)30,655,484
+/- 16,617,730
Long-term Liabilities
Long term Debt 21,075,824
Capital Lease Obligations Min Short Term Debt722,589
Long-term Liabilities Other 0
Long-term Liabilities  (as reported)28,513,058
Long-term Liabilities  (calculated)21,798,413
+/- 6,714,644
Total Stockholder Equity
Retained Earnings 23,230,219
Total Stockholder Equity (as reported)113,137,529
Total Stockholder Equity (calculated)23,230,219
+/- 89,907,310
Other
Capital Stock20,201,681
Common Stock Shares Outstanding 16,183
Net Debt 24,531,605
Net Invested Capital 153,087,483
Net Working Capital 46,821,596
Property Plant and Equipment Gross 124,090,761



Balance Sheet

Currency in KRW. All numbers in thousands.

 Trend2023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-09-302017-06-302017-03-31
> Total Assets 
111,299,322
116,026,738
120,929,111
124,817,754
143,576,272
139,801,999
135,226,315
133,061,683
134,423,160
133,143,777
137,718,627
140,247,263
152,933,846
149,987,267
154,901,007
160,113,574
192,449,373
195,642,654
192,985,288
195,777,196
192,544,305
189,858,207
195,205,073
196,576,561
200,585,523
196,582,950
196,582,950200,585,523196,576,561195,205,073189,858,207192,544,305195,777,196192,985,288195,642,654192,449,373160,113,574154,901,007149,987,267152,933,846140,247,263137,718,627133,143,777134,423,160133,061,683135,226,315139,801,999143,576,272124,817,754120,929,111116,026,738111,299,322
   > Total Current Assets 
56,641,299
60,539,427
64,014,321
66,231,431
81,697,009
73,027,004
68,869,662
66,131,225
68,086,393
63,126,265
65,053,890
64,572,812
73,568,334
69,723,565
64,466,555
70,008,522
102,240,600
103,978,440
98,887,922
100,846,644
96,687,090
94,788,753
96,357,746
97,504,992
100,266,121
94,094,809
94,094,809100,266,12197,504,99296,357,74694,788,75396,687,090100,846,64498,887,922103,978,440102,240,60070,008,52264,466,55569,723,56573,568,33464,572,81265,053,89063,126,26568,086,39366,131,22568,869,66273,027,00481,697,00966,231,43164,014,32160,539,42756,641,299
       Cash And Cash Equivalents 
18,905,063
18,485,350
18,382,486
21,828,999
39,655,057
31,205,671
26,966,546
17,063,590
25,459,963
24,289,345
26,846,233
25,148,776
31,367,244
24,808,217
20,322,824
22,594,974
54,765,245
53,222,308
50,263,468
49,313,967
42,241,751
36,054,466
25,838,582
24,675,923
24,908,248
18,010,839
18,010,83924,908,24824,675,92325,838,58236,054,46642,241,75149,313,96750,263,46853,222,30854,765,24522,594,97420,322,82424,808,21731,367,24425,148,77626,846,23324,289,34525,459,96317,063,59026,966,54631,205,67139,655,05721,828,99918,382,48618,485,35018,905,063
       Short-term Investments 
500,000
1,419,443
600,039
500,000
0
500,000
0
7,551,886
140,000
200,000
0
0
0
60,000
180,000
150,000
300,000
450,000
0
0
0
0
4,939,055
2,660,645
1,200,000
1,000,000
1,000,0001,200,0002,660,6454,939,0550000450,000300,000150,000180,00060,000000200,000140,0007,551,8860500,0000500,000600,0391,419,443500,000
       Net Receivables 
22,116,477
22,614,293
23,438,999
22,853,885
22,419,773
21,179,114
22,431,352
19,738,031
19,366,346
17,327,655
20,500,098
20,972,160
20,722,762
19,961,766
19,907,537
22,749,285
22,281,766
23,166,759
22,793,030
26,361,175
24,837,085
25,360,591
24,816,287
20,776,023
20,624,983
25,067,536
25,067,53620,624,98320,776,02324,816,28725,360,59124,837,08526,361,17522,793,03023,166,75922,281,76622,749,28519,907,53719,961,76620,722,76220,972,16020,500,09817,327,65519,366,34619,738,03122,431,35221,179,11422,419,77322,853,88523,438,99922,614,29322,116,477
       Inventory 
14,033,761
14,878,236
18,152,972
18,110,992
16,851,943
16,954,859
15,615,956
15,890,236
16,200,882
16,167,190
17,015,981
17,689,043
21,098,362
23,909,471
23,688,893
24,023,537
24,047,600
26,144,711
25,225,284
24,756,354
28,819,331
32,248,484
39,832,040
45,090,741
49,003,343
43,252,932
43,252,93249,003,34345,090,74139,832,04032,248,48428,819,33124,756,35425,225,28426,144,71124,047,60024,023,53723,688,89323,909,47121,098,36217,689,04317,015,98116,167,19016,200,88215,890,23615,615,95616,954,85916,851,94318,110,99218,152,97214,878,23614,033,761
       Other Current Assets 
937,568
2,917,837
3,146,962
2,744,804
2,078,568
2,980,092
2,856,131
2,747,124
164,917
137,551
541,765
635,054
256,795
784,190
269,599
377,878
691,579
852,936
491,056
265,288
606,697
930,680
692,939
404,104
391,669
401,454
401,454391,669404,104692,939930,680606,697265,288491,056852,936691,579377,878269,599784,190256,795635,054541,765137,551164,9172,747,1242,856,1312,980,0922,078,5682,744,8043,146,9622,917,837937,568
   > Long-term Assets 
0
0
0
0
0
0
0
66,930,458
66,336,767
70,017,512
72,664,736
75,674,451
79,365,512
80,263,702
90,434,452
90,105,052
90,208,773
91,664,214
94,097,366
94,930,551
95,857,214
95,069,453
98,847,326
99,071,569
100,319,402
102,488,140
102,488,140100,319,40299,071,56998,847,32695,069,45395,857,21494,930,55194,097,36691,664,21490,208,77390,105,05290,434,45280,263,70279,365,51275,674,45172,664,73670,017,51266,336,76766,930,4580000000
       Property Plant Equipment 
47,601,435
48,265,440
48,728,051
50,305,510
53,131,782
55,694,726
57,811,651
58,280,468
57,544,005
60,542,549
63,262,522
65,673,977
68,132,084
68,327,265
78,073,296
77,654,974
77,603,281
79,078,110
80,341,360
81,249,534
81,424,353
80,762,384
81,371,282
81,267,879
81,500,286
81,880,009
81,880,00981,500,28681,267,87981,371,28280,762,38481,424,35381,249,53480,341,36079,078,11077,603,28177,654,97478,073,29668,327,26568,132,08465,673,97763,262,52260,542,54957,544,00558,280,46857,811,65155,694,72653,131,78250,305,51048,728,05148,265,44047,601,435
       Goodwill 
50,829
50,829
50,829
50,829
50,829
50,829
50,829
50,829
50,829
50,829
50,829
50,829
50,829
50,829
50,829
50,829
50,829
50,829
50,829
50,829
50,829
50,829
50,829
50,829
155,309
155,309
155,309155,30950,82950,82950,82950,82950,82950,82950,82950,82950,82950,82950,82950,82950,82950,82950,82950,82950,82950,82950,82950,82950,82950,82950,82950,829
       Long Term Investments 
2,722,135
2,891,226
3,087,479
3,891,499
3,824,945
4,283,274
3,927,007
3,905,571
3,790,631
4,351,232
4,025,899
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000004,025,8994,351,2323,790,6313,905,5713,927,0074,283,2743,824,9453,891,4993,087,4792,891,2262,722,135
       Intangible Assets 
1,940,474
1,915,272
1,878,967
1,810,248
1,801,700
3,508,074
1,651,933
1,642,781
1,938,929
2,044,775
1,924,693
2,513,165
3,106,139
3,522,531
3,785,501
3,686,680
3,679,818
3,623,100
4,087,102
4,071,528
4,061,061
3,973,228
3,666,483
4,029,905
4,036,511
3,675,059
3,675,0594,036,5114,029,9053,666,4833,973,2284,061,0614,071,5284,087,1023,623,1003,679,8183,686,6803,785,5013,522,5313,106,1392,513,1651,924,6932,044,7751,938,9291,642,7811,651,9333,508,0741,801,7001,810,2481,878,9671,915,2721,940,474
       Long-term Assets Other 
0
0
0
0
0
0
0
498,675
498,676
498,677
498,676
498,677
498,676
520,537
498,677
498,676
498,677
498,676
498,677
498,676
498,677
498,677
262,299
262,301
262,301
262,301
262,301262,301262,301262,299498,677498,677498,676498,677498,676498,677498,676498,677520,537498,676498,677498,676498,677498,676498,6750000000
> Total Liabilities 
33,008,376
37,268,628
40,618,501
42,252,889
57,224,915
52,639,141
48,354,059
46,148,439
46,320,790
43,926,731
47,173,960
49,570,088
62,003,127
49,021,863
37,864,566
44,452,382
62,987,933
63,545,629
64,300,209
69,224,073
66,897,698
66,973,939
71,831,031
75,838,637
77,503,955
75,786,271
75,786,27177,503,95575,838,63771,831,03166,973,93966,897,69869,224,07364,300,20963,545,62962,987,93344,452,38237,864,56649,021,86362,003,12749,570,08847,173,96043,926,73146,320,79046,148,43948,354,05952,639,14157,224,91542,252,88940,618,50137,268,62833,008,376
   > Total Current Liabilities 
31,187,838
35,261,206
38,228,254
39,061,241
37,219,216
32,307,033
27,787,568
24,331,171
24,506,435
19,725,491
42,495,630
41,090,187
44,138,859
30,674,332
18,398,703
24,429,664
27,506,236
27,333,314
30,014,749
34,148,514
56,480,592
57,547,698
64,315,528
67,261,554
49,480,488
47,273,214
47,273,21449,480,48867,261,55464,315,52857,547,69856,480,59234,148,51430,014,74927,333,31427,506,23624,429,66418,398,70330,674,33244,138,85941,090,18742,495,63019,725,49124,506,43524,331,17127,787,56832,307,03337,219,21639,061,24138,228,25435,261,20631,187,838
       Short-term Debt 
16,900,000
16,900,000
18,070,000
22,379,908
37,577,694
0
866,197
8,575,654
6,071,626
5,874,376
23,437,558
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000023,437,5585,874,3766,071,6268,575,654866,197037,577,69422,379,90818,070,00016,900,00016,900,000
       Short Long Term Debt 
16,900,000
16,900,000
18,070,000
22,379,908
37,577,694
0
866,197
8,575,654
6,071,626
5,874,376
23,437,558
23,799,764
25,165,378
14,696,884
4,388,496
7,391,394
9,742,219
7,097,269
10,012,370
9,556,557
35,593,562
36,083,400
36,882,096
38,068,299
24,804,980
21,466,620
21,466,62024,804,98038,068,29936,882,09636,083,40035,593,5629,556,55710,012,3707,097,2699,742,2197,391,3944,388,49614,696,88425,165,37823,799,76423,437,5585,874,3766,071,6268,575,654866,197037,577,69422,379,90818,070,00016,900,00016,900,000
       Accounts payable 
4,646,888
6,579,355
11,757,483
6,909,880
7,928,393
4,285,877
5,056,812
4,771,569
5,497,053
3,338,947
6,385,086
6,674,980
8,346,846
7,471,893
5,286,763
6,147,512
8,622,028
10,203,640
8,982,265
10,900,922
10,653,516
10,804,178
15,840,532
16,107,455
13,803,051
9,179,299
9,179,29913,803,05116,107,45515,840,53210,804,17810,653,51610,900,9228,982,26510,203,6408,622,0286,147,5125,286,7637,471,8938,346,8466,674,9806,385,0863,338,9475,497,0534,771,5695,056,8124,285,8777,928,3936,909,88011,757,4836,579,3554,646,888
       Other Current Liabilities 
9,151,331
11,422,188
8,124,334
10,495,405
8,470,455
9,022,579
9,508,259
1
0
1
11,240,200
9,290,218
9,141,338
6,972,583
6,821,285
9,097,671
7,358,030
8,329,141
9,051,745
11,837,136
8,137,658
8,591,225
9,437,099
-1
9,565
9,565
9,5659,565-19,437,0998,591,2258,137,65811,837,1369,051,7458,329,1417,358,0309,097,6716,821,2856,972,5839,141,3389,290,21811,240,2001019,508,2599,022,5798,470,45510,495,4058,124,33411,422,1889,151,331
   > Long-term Liabilities 
0
0
0
0
0
0
0
21,817,268
21,814,355
24,201,240
4,678,330
8,479,901
17,864,268
18,347,531
19,465,862
20,022,719
35,481,696
36,212,314
34,285,461
35,075,559
10,417,106
9,426,241
7,515,503
8,577,083
28,023,467
28,513,058
28,513,05828,023,4678,577,0837,515,5039,426,24110,417,10635,075,55934,285,46136,212,31435,481,69620,022,71919,465,86218,347,53117,864,2688,479,9014,678,33024,201,24021,814,35521,817,2680000000
       Capital Lease Obligations 
0
0
0
0
0
0
0
855,718
977,618
920,596
822,480
760,926
923,589
944,788
969,614
979,419
911,192
804,037
697,754
934,163
937,389
770,467
793,825
599,162
784,296
722,589
722,589784,296599,162793,825770,467937,389934,163697,754804,037911,192979,419969,614944,788923,589760,926822,480920,596977,618855,7180000000
       Long-term Liabilities Other 
0
0
0
0
0
0
0
-1
1
0
0
-1
0
0
0
0
0
0
0
0
0
0
0
259,128
0
0
00259,12800000000000-1001-10000000
> Total Stockholder Equity
75,864,165
76,214,331
78,098,045
80,233,571
83,994,212
84,755,921
84,494,850
85,647,165
86,690,124
87,585,260
88,694,578
88,502,479
88,346,531
98,062,932
114,359,483
112,718,384
125,580,773
127,837,082
124,281,212
121,929,036
120,512,937
117,321,103
116,816,212
113,818,041
115,877,694
113,137,529
113,137,529115,877,694113,818,041116,816,212117,321,103120,512,937121,929,036124,281,212127,837,082125,580,773112,718,384114,359,48398,062,93288,346,53188,502,47988,694,57887,585,26086,690,12485,647,16584,494,85084,755,92183,994,21280,233,57178,098,04576,214,33175,864,165
   Common Stock
6,538,246
6,538,246
6,538,246
6,745,427
6,745,427
6,745,427
6,745,427
6,745,427
6,745,427
6,745,427
6,745,427
6,745,427
6,745,427
7,514,653
8,412,087
15,870,785
17,112,504
17,609,191
17,609,191
17,609,191
17,609,191
17,609,191
17,609,191
0
0
0
00017,609,19117,609,19117,609,19117,609,19117,609,19117,609,19117,112,50415,870,7858,412,0877,514,6536,745,4276,745,4276,745,4276,745,4276,745,4276,745,4276,745,4276,745,4276,745,4276,745,4276,538,2466,538,2466,538,246
   Retained Earnings 
31,851,944
32,107,138
33,896,939
35,205,447
38,744,792
39,200,607
39,690,638
36,689,584
40,633,888
38,833,444
42,716,573
43,353,565
42,286,167
42,964,967
41,914,283
40,324,081
40,705,866
40,106,650
36,540,363
34,193,633
32,779,143
30,678,420
31,395,871
29,199,260
25,982,444
23,230,219
23,230,21925,982,44429,199,26031,395,87130,678,42032,779,14334,193,63336,540,36340,106,65040,705,86640,324,08141,914,28342,964,96742,286,16743,353,56542,716,57338,833,44440,633,88836,689,58439,690,63839,200,60738,744,79235,205,44733,896,93932,107,13831,851,944
   Capital Surplus 00000000000000000000000000
   Treasury Stock00000000000000000000000000
   Other Stockholders Equity 
8,876,777
8,971,748
9,021,878
9,446,168
6,691,762
6,907,569
6,624,950
6,593,820
6,508,580
6,259,941
6,302,236
6,193,862
6,215,473
6,187,934
13,639,237
13,588,339
13,130,583
13,096,630
13,107,048
13,101,602
13,099,993
13,066,761
12,571,776
0
0
0
00012,571,77613,066,76113,099,99313,101,60213,107,04813,096,63013,130,58313,588,33913,639,2376,187,9346,215,4736,193,8626,302,2366,259,9416,508,5806,593,8206,624,9506,907,5696,691,7629,446,1689,021,8788,971,7488,876,777



Balance Sheet

Currency in KRW. All numbers in thousands.




Cash Flow

Currency in KRW. All numbers in thousands.




Income Statement

Currency in KRW. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue137,339,548
Cost of Revenue-86,082,473
Gross Profit51,257,07551,257,075
 
Operating Income (+$)
Gross Profit51,257,075
Operating Expense-137,650,145
Operating Income-310,597-86,393,070
 
Operating Expense (+$)
Research Development9,060,589
Selling General Administrative16,236,003
Selling And Marketing Expenses-
Operating Expense137,650,14525,296,592
 
Net Interest Income (+$)
Interest Income830,503
Interest Expense-2,157,930
Other Finance Cost-1,557
Net Interest Income-1,325,870
 
Pretax Income (+$)
Operating Income-310,597
Net Interest Income-1,325,870
Other Non-Operating Income Expenses-
Income Before Tax (EBT)-5,648,418-310,597
EBIT - interestExpense = -2,157,930
-8,303,512
-6,145,582
Interest Expense2,157,930
Earnings Before Interest and Taxes (EBIT)--3,490,488
Earnings Before Interest and Taxes (EBITDA)-
 
After tax Income (+$)
Income Before Tax-5,648,418
Tax Provision-1,150,784
Net Income From Continuing Ops-6,799,202-6,799,202
Net Income-8,303,512
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net-1,325,870
 

Technical Analysis of Yuyu
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Yuyu. The general trend of Yuyu is BEARISH with 57.1% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Yuyu's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-57.1%) Bearish trend (57.1%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Yuyu Pharma Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is -1/(-1 +1).

  • Around resistance: The price is trading arround resistance levels. This can be considered as a potential exit level. -1

The bullish price targets are: 11,820 < 11,870 < 13,070.

The bearish price targets are: 11,390 > 10,850 > 9,920.

Tweet this
Yuyu Pharma Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Yuyu Pharma Inc. The current mas is .

The long score for the Moving Averages is 3/14.
The longshort score for the Moving Averages is -8/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Yuyu Pharma Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Yuyu Pharma Inc. The current macd is -222.67301163.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Yuyu price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Yuyu. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Yuyu price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Yuyu Pharma Inc Daily Moving Average Convergence/Divergence (MACD) ChartYuyu Pharma Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Yuyu Pharma Inc. The current adx is 12.83.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -1/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Yuyu shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
Yuyu Pharma Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Yuyu Pharma Inc. The current sar is 12,181.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Yuyu Pharma Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Yuyu Pharma Inc. The current rsi is 33.20. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending down: The RSI is trending down. -1
Yuyu Pharma Inc Daily Relative Strength Index (RSI) ChartYuyu Pharma Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Yuyu Pharma Inc. The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -6/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Yuyu price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Yuyu Pharma Inc Daily Stochastic Oscillator ChartYuyu Pharma Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Yuyu Pharma Inc. The current cci is -179.3409379.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
Yuyu Pharma Inc Daily Commodity Channel Index (CCI) ChartYuyu Pharma Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Yuyu Pharma Inc. The current cmo is -49.61457263.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Yuyu Pharma Inc Daily Chande Momentum Oscillator (CMO) ChartYuyu Pharma Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Yuyu Pharma Inc. The current willr is -100.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Yuyu Pharma Inc Daily Williams %R ChartYuyu Pharma Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Yuyu Pharma Inc.

Yuyu Pharma Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Yuyu Pharma Inc. The current atr is 290.77.

Yuyu Pharma Inc Daily Average True Range (ATR) ChartYuyu Pharma Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Yuyu Pharma Inc. The current obv is 62,054.

Yuyu Pharma Inc Daily On-Balance Volume (OBV) ChartYuyu Pharma Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Yuyu Pharma Inc. The current mfi is 31.56.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Yuyu Pharma Inc Daily Money Flow Index (MFI) ChartYuyu Pharma Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Yuyu Pharma Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-03MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2023-11-06STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-07STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-08STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-09WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-11-13SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2023-11-14STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-17CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-11-20SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-11-21ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-11-22STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-24STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-27RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-11-28CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-11-29RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-11-30STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-01STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-05SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-07CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-08RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-11MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2023-12-12CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-15CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-12-22STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-26STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-27STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-28MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-03MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-01-05SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-08MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-09STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-12STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-01-15STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-16CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-17STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-19STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-22MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-23STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-24STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-30STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-31STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-01STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-08MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-02-13CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-14CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-16CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-20CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-21SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-02-22STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-23CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-26CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-27CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-29SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-04STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-05MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-06DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-03-07STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-08DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-03-11CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-13STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-03-15STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-18CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-19DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-03-20STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-21DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-03-22STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-25DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-26DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-03-27DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-28STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.

6.3. Candlestick Patterns

Yuyu Pharma Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Yuyu Pharma Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5033.203
Ma 20Greater thanMa 5012,106.000
Ma 50Greater thanMa 10012,451.800
Ma 100Greater thanMa 20012,924.000
OpenGreater thanClose11,740.000
Total2/5 (40.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Yuyu with someone you think should read this too:
  • Are you bullish or bearish on Yuyu? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Yuyu? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Yuyu Pharma Inc

I send you an email if I find something interesting about Yuyu Pharma Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Yuyu Pharma Inc.

Receive notifications about Yuyu Pharma Inc in your mailbox!